Safety of Different Weight-Based Dosing Strategies of Intravenous Acyclovir in Obese Patients: A Retrospective Cohort Study
Annals of Pharmacotherapy · 2025
DOI: 10.1177/10600280251318017 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Annals of Pharmacotherapy, 2025. Verfasst von Mohamed Omar Saad und 4 weiteren Autor:innen. Beteiligte Einrichtung: Pharmacy Department, Al-Wakra Hospital, Hamad Medical Corporation, Doha, Qatar. Hauptthemen laut MEDLINE: Acyclovir, Obesity, Acute Kidney Injury, Antiviral Agents. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 25 Literaturangaben.
Abstract (Originalsprache)
Background
In obese patients receiving intravenous (IV) acyclovir, conflicting data exist regarding the risk of acute kidney injury (AKI) with different weight-based dosing strategies: total body weight (TBW), adjusted body weight (AdjBW), and ideal body weight (IBW).
Objective
We aimed to compare the safety of the 3 dosing strategies in obese patients.
Methods
A retrospective cohort study including obese patients who received IV acyclovir during their inpatient admissions. Patients were categorized into TBW, AdjBW, or IBW groups based on the received doses. The primary outcome was the incidence of AKI. Other outcomes included the need for renal replacement therapy (RRT), neurotoxicity, length of stay (LOS), and in-hospital mortality.
Results
A total of 339 patients were included: 196 patients in TBW group, 86 patients in AdjBW group, and 57 patients in IBW group. The AKI developed in 17.3%, 11.6%, and 7% of TBW, AdjBW and IBW groups, respectively. After adjustment for confounders, reduced dosing (AdjBW or IBW) was associated with fewer AKI compared with TBW dosing (adjusted odds ratio (aOR) [95% CI] = 0.39 [0.19, 0.82]). Compared with TBW, IBW was associated with fewer AKI (aOR [95% CI] = 0.27 [0.08, 0.85]), but AdjBW was not (aOR [95% CI] = 0.48 [0.21, 1.09]). Median LOS was numerically longer with IBW but was not significantly different from other groups. The need for RRT, neurotoxicity, and mortality did not differ between groups. Conclusion and Relevance: In obese patients, either AdjBW or IBW dosing of IV acyclovir appears to be safer than TBW. The IBW dosing had the lowest odds of AKI among the 3 dosing strategies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Pharmacy Department, Al-Wakra Hospital, Hamad Medical Corporation, Doha, Qatar.
- College of Pharmacy, Qatar University, Doha, Qatar.
ORCID-Profile: Mohamed Omar Saad, Safeya Omar Habib, Ahmed Mohammed Alhomosy, Islam Mohamed Salem, Ola Mohamad Hishari
Zitieren
APA
Saad, M. O., Habib, S. O., Alhomosy, A. M., Salem, I. M., & Hishari, O. M. (2025). Safety of Different Weight-Based Dosing Strategies of Intravenous Acyclovir in Obese Patients: A Retrospective Cohort Study. Annals of Pharmacotherapy. https://doi.org/10.1177/10600280251318017
Vancouver
Saad MO, Habib SO, Alhomosy AM, Salem IM, Hishari OM. Safety of Different Weight-Based Dosing Strategies of Intravenous Acyclovir in Obese Patients: A Retrospective Cohort Study. Annals of Pharmacotherapy. 2025. doi:10.1177/10600280251318017
BibTeX
@article{Saad2025,
author = {Saad, Mohamed Omar and Habib, Safeya Omar and Alhomosy, Ahmed Mohammed and Salem, Islam Mohamed and Hishari, Ola Mohamad},
title = {Safety of Different Weight-Based Dosing Strategies of Intravenous Acyclovir in Obese Patients: A Retrospective Cohort Study},
journal = {Annals of Pharmacotherapy},
year = {2025},
doi = {10.1177/10600280251318017}
}
EUVIMED